ImmunityBio (IBRX) is trading higher as investors react to the company’s stated progress in addressing an FDA promotional compliance issue related to ANKTIVA. In an April 6, 2026 filing and attached release, the company said it submitted a comprehensive response to the FDA Office of Prescription Drug Promotion Warning Letter dated March 13, 2026, including corrective actions and enhanced review and training steps; it also said the identified podcast was removed and that the TV advertisement cited by the FDA was never broadcast.

For commercial-stage biotechs, promotional compliance headlines can weigh on sentiment because they raise the risk of heightened regulatory scrutiny, added compliance costs, and potential limits on marketing practices. Today’s move suggests some investors are treating the company’s response and remediation plan as reducing near-term uncertainty around ANKTIVA’s promotional pathway, even as the broader regulatory process remains separate from advertising oversight.

The company’s investor relations calendar shows participation in the Goldman Sachs 47th Annual Global Healthcare Conference on May 5–8, 2026, which can act as a near-term catalyst if management provides incremental detail on commercialization, compliance follow-through, or upcoming clinical/regulatory milestones. Separately, IBRX has remained a high-volatility name with elevated short interest metrics recently cited by market data services, which can magnify intraday moves on incremental news flow.